Loading
Life sciences · Journal article
Medcomm · September 25, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Cancer remains a critical global health concern due to late detection, drug resistance, and high mortality. Mesothelin (MSLN) is a glycoprotein highly expressed on the surface of various cancer cells, including those of ovarian, pancreatic, and gastric cancers. Thus, it could be a valuable target for both as a biomarker and for immunotherapy. This review summarizes MSLN biology in cancer, current immunotherapeutic strategies targeting MSLN, associated clinical challenges, and emerging avenues to enhance immunotherapy efficacy. During cancer progression, MSLN acts as a cellular accelerator, promoting cell division and survival. It activates several critical signaling pathways, including nuclear factor k‐light‐chain‐enhancer of activated B cells (NF‐κB), interleukin‐6 and its soluble receptor (IL‐6/sIL‐6R), and c‐Jun N‐terminal kinase (JNK), thereby promoting epithelial–mesenchymal transition and angiogenesis. Various MSLN‐targeting immunotherapies, including monoclonal antibodies, chimeric antigen receptor‐T cells, cytokine therapies, and vaccines, have shown preclinical and early clinical efficacy. However, immune evasion, an immunosuppressive tumor microenvironment, antigen heterogeneity, tumor immune escape, and off‐tumor toxicities continue to hinder the broad clinical success of these modalities. Nonetheless, rational combinations of MSLN‐directed therapies with other immunomodulatory strategies, optimized patient stratification, and advances in vaccine and adoptive cell therapy design hold promise for overcoming resistance and improving patient outcomes.